IL145829A0 - Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1 - Google Patents

Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1

Info

Publication number: IL145829A0
Authority: IL; Israel
Prior art keywords: glucagon; activates; peptide; receptor; compound
Prior art date: 1999-04-30

Application number

IL14582900A

Other languages

English (en)

Original Assignee

Bionebraska Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-30

Filing date

2000-05-01

Publication date

2002-07-25

2000-05-01 Application filed by Bionebraska Inc filed Critical Bionebraska Inc

2002-07-25 Publication of IL145829A0 publication Critical patent/IL145829A0/xx

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
102100040918 Pro-glucagon Human genes 0.000 title abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
208000013016 Hypoglycemia Diseases 0.000 abstract 2
230000002218 hypoglycaemic effect Effects 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
102000051325 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
208000032843 Hemorrhage Diseases 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
208000006011 Stroke Diseases 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000003914 insulin secretion Effects 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

IL14582900A 1999-04-30 2000-05-01 Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1 IL145829A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/303,016 US6429197B1 (en)	1998-10-08	1999-04-30	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
PCT/US2000/011652 WO2000066142A2 (en)	1999-04-30	2000-05-01	Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain

Publications (1)

Publication Number	Publication Date
IL145829A0 true IL145829A0 (en)	2002-07-25

Family

ID=23170209

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14582900A IL145829A0 (en)	1999-04-30	2000-05-01	Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1

Country Status (14)

Country	Link
US (2)	US6429197B1 (de)
EP (1)	EP1187628B1 (de)
JP (1)	JP2002543145A (de)
CN (1)	CN1376072A (de)
AT (1)	ATE369873T1 (de)
AU (2)	AU774084B2 (de)
CA (1)	CA2368772C (de)
DE (1)	DE60035987T2 (de)
ES (1)	ES2290029T3 (de)
IL (1)	IL145829A0 (de)
MX (1)	MXPA01010937A (de)
NO (1)	NO20015298L (de)
NZ (1)	NZ514609A (de)
WO (1)	WO2000066142A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6849708B1 (en) *	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6924264B1 (en)	1999-04-30	2005-08-02	Amylin Pharmaceuticals, Inc.	Modified exendins and exendin agonists
US20060160740A1 (en) *	1999-10-21	2006-07-20	Suad Efendic	Use of GLP-1 or analogs in treatment of stroke
EP2206720A1 (de)	2000-04-12	2010-07-14	Human Genome Sciences, Inc.	Albuminfusionsproteine
ATE397938T1 (de) *	2000-05-19	2008-07-15	Amylin Pharmaceuticals Inc	Behandlung des akuten koronaren syndroms mit glp- 1
ATE424413T1 (de) *	2000-06-16	2009-03-15	Lilly Co Eli	Analoge des glucagon-ähnlichen peptids-1
CA2430934C (en)	2000-12-01	2011-06-21	Takeda Chemical Industries, Ltd.	A method of producing sustained-release preparations of a bioactive substance using high-pressure gas
JP2002293799A (ja) *	2001-03-29	2002-10-09	Itoham Foods Inc	新規ペプチド及びそれを含有する消化管運動抑制剤
EP1411968B1 (de) *	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp 1 exendin 4 peptidanaloga und deren verwendungen
EP2261250B1 (de)	2001-12-21	2015-07-01	Human Genome Sciences, Inc.	GCSF-Albumin Fusionsproteine
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2004071393A2 (en) *	2003-02-13	2004-08-26	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with glucagon-like peptide 1 receptor (glp1r)
EP1617888B1 (de)	2003-04-23	2019-06-12	Valeritas, Inc.	Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
CA2550217A1 (en) *	2003-12-12	2005-07-07	Michael A. Brownlee	Glp-1 (9-36) methods and compositions
US20080194483A1 (en) *	2003-12-12	2008-08-14	Brownlee Michael A	GLP-1 (9-36) methods and compositions
WO2006014425A1 (en)	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
CN103239773B (zh)	2006-03-30	2015-08-26	瓦莱里塔斯公司	多筒式流体递送器械
US8986253B2 (en)	2008-01-25	2015-03-24	Tandem Diabetes Care, Inc.	Two chamber pumps and related methods
WO2010013012A2 (en) *	2008-08-01	2010-02-04	Lund University Bioscience Ab	Novel polypeptides and uses thereof
US8408421B2 (en)	2008-09-16	2013-04-02	Tandem Diabetes Care, Inc.	Flow regulating stopcocks and related methods
AU2009293019A1 (en)	2008-09-19	2010-03-25	Tandem Diabetes Care Inc.	Solute concentration measurement device and related methods
EP3284494A1 (de)	2009-07-30	2018-02-21	Tandem Diabetes Care, Inc.	Tragbares infusionspumpensystem
CN101706297B (zh) *	2009-08-10	2012-10-17	浙江鼎立实业有限公司	数显式微压和微流量综合检测台
US9180242B2 (en)	2012-05-17	2015-11-10	Tandem Diabetes Care, Inc.	Methods and devices for multiple fluid transfer
US9555186B2 (en)	2012-06-05	2017-01-31	Tandem Diabetes Care, Inc.	Infusion pump system with disposable cartridge having pressure venting and pressure feedback
EP2873422A4 (de)	2012-07-10	2015-12-30	Takeda Pharmaceutical	Pharmazeutische zubereitung zur injektion
CN103566354B (zh) *	2012-07-25	2017-12-05	江苏豪森药业集团有限公司	含有glp‑1类似物的衍生物或其可药用盐的药物组合物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HK1211232A1 (en)	2012-12-21	2016-05-20	Sanofi	Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
US9173998B2 (en)	2013-03-14	2015-11-03	Tandem Diabetes Care, Inc.	System and method for detecting occlusions in an infusion pump
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
ES2909074T3 (es) *	2016-05-06	2022-05-05	Phasebio Pharmaceuticals Inc	Proteínas de fusión ELP para liberación controlada y sostenida

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4196196A (en) *	1978-06-19	1980-04-01	Tiholiz Ivan C	Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
US4976959A (en) *	1986-05-12	1990-12-11	Burroughs Wellcome Co.	T-PA and SOD in limiting tissue damage
US6204259B1 (en) *	1993-01-14	2001-03-20	Monsanto Company	Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5373016A (en)	1993-05-28	1994-12-13	Zeneca, Inc.	Protection of isothiazolinone biocides from free radicals
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US6277819B1 (en)	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
EP0996459B1 (de)	1997-01-07	2005-09-21	Amylin Pharmaceuticals, Inc.	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
US5846937A (en)	1997-03-03	1998-12-08	1149336 Ontario Inc.	Method of using exendin and GLP-1 to affect the central nervous system
WO1998043658A1 (en) *	1997-03-31	1998-10-08	Eli Lilly And Company	Glucagon-like peptide-1 analogs
MY155270A (en) *	1998-09-24	2015-09-30	Lilly Co Eli	Use of glp-1 or analogs in treatment of stroke
US6284725B1 (en)	1998-10-08	2001-09-04	Bionebraska, Inc.	Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
WO2002034285A2 (en)	2000-10-20	2002-05-02	Coolidge Thomas R	Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide

1999
- 1999-04-30 US US09/303,016 patent/US6429197B1/en not_active Ceased
2000
- 2000-05-01 CA CA2368772A patent/CA2368772C/en not_active Expired - Fee Related
- 2000-05-01 IL IL14582900A patent/IL145829A0/xx not_active IP Right Cessation
- 2000-05-01 EP EP00928616A patent/EP1187628B1/de not_active Expired - Lifetime
- 2000-05-01 ES ES00928616T patent/ES2290029T3/es not_active Expired - Lifetime
- 2000-05-01 AT AT00928616T patent/ATE369873T1/de not_active IP Right Cessation
- 2000-05-01 AU AU46825/00A patent/AU774084B2/en not_active Ceased
- 2000-05-01 DE DE60035987T patent/DE60035987T2/de not_active Expired - Lifetime
- 2000-05-01 MX MXPA01010937A patent/MXPA01010937A/es active IP Right Grant
- 2000-05-01 WO PCT/US2000/011652 patent/WO2000066142A2/en not_active Ceased
- 2000-05-01 JP JP2000615026A patent/JP2002543145A/ja active Pending
- 2000-05-01 NZ NZ514609A patent/NZ514609A/xx not_active IP Right Cessation
- 2000-05-01 CN CN00806935A patent/CN1376072A/zh active Pending
2001
- 2001-10-29 NO NO20015298A patent/NO20015298L/no not_active Application Discontinuation
2004
- 2004-08-06 US US10/913,309 patent/USRE41288E1/en not_active Expired - Lifetime
- 2004-09-15 AU AU2004212547A patent/AU2004212547B2/en not_active Ceased

Also Published As

Publication number	Publication date
EP1187628A2 (de)	2002-03-20
WO2000066142A3 (en)	2002-01-24
NO20015298L (no)	2001-12-28
WO2000066142A2 (en)	2000-11-09
AU2004212547B2 (en)	2008-03-20
CA2368772C (en)	2011-11-15
USRE41288E1 (en)	2010-04-27
CN1376072A (zh)	2002-10-23
NO20015298D0 (no)	2001-10-29
DE60035987D1 (de)	2007-09-27
AU2004212547A1 (en)	2004-10-14
CA2368772A1 (en)	2000-11-09
ATE369873T1 (de)	2007-09-15
ES2290029T3 (es)	2008-02-16
MXPA01010937A (es)	2002-05-06
AU774084B2 (en)	2004-06-17
NZ514609A (en)	2004-03-26
JP2002543145A (ja)	2002-12-17
EP1187628B1 (de)	2007-08-15
US6429197B1 (en)	2002-08-06
DE60035987T2 (de)	2008-05-08
AU4682500A (en)	2000-11-17

Legal Events

Date	Code	Title	Description
2014-04-30	KB	Patent renewed
2018-11-29	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
IL145829A0 (en)	2002-07-25	Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1
Gough et al.	2013	Insulin degludec: overview of a novel ultra long‐acting basal insulin
MXPA05006994A (es)	2005-10-18	Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
Holst	2004	Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
JP6403670B2 (ja)	2018-10-10	持続型インスリン及びインスリン分泌性ペプチドの液状製剤
EP4549454A3 (de)	2025-07-09	Gip/glp1-co-agonistverbindungen
IL165531A0 (en)	2006-01-15	GLP-1 and methods for treating diabetes
MX9504380A (es)	1997-06-28	Composiciones, analogos de peptido insulinotropico semejante a glucagon y metodos de uso de los mismos.
RU2015101826A (ru)	2016-08-20	Применение долгодействующих пептидов glp-1
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
IL307966A (en)	2023-12-01	Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
CA2373266A1 (en)	2000-12-07	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
CA2138161A1 (en)	1993-12-23	Glucagon-like peptide and insulinotropin derivatives
IN2012DN03921A (de)	2015-09-04
AU2003234529A8 (en)	2003-12-12	Glp-1 gene delivery for the treatment of type 2 diabetes
MXPA05007857A (es)	2005-10-18	Moduladores derivados de indol de receptores nucleares de hormonas esteroideas.
WO2003053339A3 (en)	2005-04-14	Insulin molecule having protracted time action
ATE525102T1 (de)	2011-10-15	Spritzenanordnung mit strahlungsabschirmung
MXPA02007117A (es)	2004-08-23	Composiciones para suministrar un antagonista de cortisol..
EA200400658A1 (ru)	2004-10-28	Способ лечения опухолей, экспрессирующих рецептор для ил-13 (варианты)
RU2015146982A (ru)	2017-05-11	Лечение сахарного диабета с помощью составов инсулинов длительного действия
MY155219A (en)	2015-09-30	Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
IL146868A0 (en)	2002-08-14	A pharmaceutical composition containing an igf-i/igfbp-3 complex
MX2025011915A (es)	2025-11-03	Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
MY138246A (en)	2009-05-29	Treatment of diabetes with thiazolidione and sulphonylurea.